Clinical Trials Logo

Clinical Trial Summary

This prospective, interventional, controlled study is aimed to evaluate the efficacy and safety of cyclophosphamide in the treatment of idiopathic retroperitoneal fibrosis, which refers to the chronic nonspecific inflammation of retroperitoneal fascia and adipose tissue that gradually evolves into fibroproliferative disease.


Clinical Trial Description

Idiopathic retroperitoneal fibrosis is a chronic disease that requires treatment for a few years. Patients with this disease respond well to glucocorticoid therapy, so you need to take glucocorticoid medication once the diagnosis is established. In addition, most patients need to use immunosuppressants when taking glucocorticoids. At present, the most commonly used immunosuppressants in the world are cyclophosphamide, azathioprine, methotrexate and mycophoranate, etc. The function of the above drugs is to improve the disorder of the immune system function, in order to restore the normal immune state, so that the inflammation and swelling of the affected organs disappear, restore the normal function. It should be emphasized that if the use of hormones and immunosuppressant is not standard or stopped too early, it can lead to disease recurrence. Therefore, after the disease is under control, long-term adherence to medication is needed to maintain a stable state of the disease. At present, there is no clear treatment guideline for idiopathic retroperitoneal fibrosis in the world, and the addition of immunosuppressant is also out of debate. Therefore, a comprehensive evaluation of its pathogenesis, clinical characteristics and treatment response is needed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04762810
Study type Interventional
Source Peking Union Medical College Hospital
Contact
Status Recruiting
Phase Phase 4
Start date January 3, 2020
Completion date February 10, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05428826 - Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis Phase 4
Recruiting NCT01240850 - Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial Phase 3
Recruiting NCT04314323 - National Registry of IRPF in China
Recruiting NCT04762784 - A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis Phase 4
Recruiting NCT04312854 - A Prospective Cohort Study of IRPF in China